Immunotherapy for Solid Tumours: Current Clinical Landscape and Future Directions

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Cancer immunotherapy has revolutionized oncology, with significant success in specific cancers like melanoma and non-small cell lung cancer.
• Despite successes, immunotherapy's efficacy in most solid tumors is limited by biological and physical barriers within the tumor microenvironment (TME).

Purpose of the Study:

• To provide a comprehensive overview of immunotherapy for solid tumors.
• To discuss mechanisms of immune resistance, the role of the TME, and factors contributing to therapeutic failure.
• To explore strategies for overcoming barriers and enhancing immunotherapy efficacy.

Main Methods:

• Review of current literature on cancer immunotherapy and the tumor microenvironment.
• Analysis of biological and physical barriers limiting immunotherapy effectiveness.
• Exploration of strategies to convert 'cold' tumors to 'hot' tumors.

Main Results:

• The immunosuppressive TME, characterized by chronic inflammation and suppressive cells, hinders immune cell function.
• Physical barriers like high intra-tumoral pressure and abnormal vasculature impede drug delivery and immune cell trafficking.
• Strategies to overcome these barriers are being developed to improve immunotherapy responses.

Conclusions:

• Understanding complex tumor-immune interactions is crucial for improving immunotherapy outcomes.
• Addressing both immunological and physical barriers is essential for broadening immunotherapy benefits.
• Future approaches aim to enhance patient stratification and identify predictive biomarkers for better treatment selection.